CJC-1295 DAC
Long-acting growth hormone-releasing hormone analog with DAC
CJC-1295 DAC is a long-acting experimental GHRH analogue. Early studies show sustained increases in GH and IGF-1, but it is not an approved therapy and long-term benefit is unproven.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
This profile concerns albumin-binding CJC-1295 with DAC from the human studies, not the inconsistent NO DAC market term.
- Human research
- Limited
- Replication
- Single research group
- Clinical endpoints
- Surrogate measures
- Safety
- Limited characterization
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
Measured half-life
5.8 to 8.1 days in early human studies
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295Human study2006
U.S. National Library of Medicine (PubMed)
Accessed:
Research gaps
- ·No marketing authorization
- ·Small early studies without long-term patient-relevant outcomes
- ·Limited safety data
Mechanism
CJC-1295 activates pituitary GHRH receptors. Its DAC modification binds albumin and prolongs exposure.
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295Human study2006
U.S. National Library of Medicine (PubMed)
Accessed:
- CJC-1295 preserves growth hormone pulsatility in healthy adultsHuman study2006
U.S. National Library of Medicine (PubMed)
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·FDA cites increased heart rate and a systemic vasodilatory reaction among reported serious events.
Contraindications and warnings
- ·Contraindications have not been established for an approved use.
Interactions
- ·Interactions for the research or product forms described here have not been adequately studied.
Research gaps
- ·No marketing authorization
- ·Small early studies without long-term patient-relevant outcomes
- ·Limited safety data
- FDA: Safety risks associated with CJC-1295 in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 2
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295Human study2006
U.S. National Library of Medicine (PubMed)
Accessed:
- CJC-1295 preserves growth hormone pulsatility in healthy adultsHuman study2006
U.S. National Library of Medicine (PubMed)
Accessed:
- FDA: Safety risks associated with CJC-1295 in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed: